Karyopharm Therapeutics (KPTI) EBIT Margin (2012 - 2026)
Karyopharm Therapeutics' (KPTI) quarterly EBIT Margin came in at 52.36% in Q4 2025, up 5006.0% YoY from 1.03% in Q4 2024, and down 51.52% on a QoQ basis from 34.56% in Q3 2025.
Karyopharm Therapeutics (KPTI) EBIT Margin (2012 - 2026) Analysis & Trends
Karyopharm Therapeutics (KPTI) has 14 years of EBIT Margin data on file, last reported at 52.36% in Q4 2025.
- Quarterly EBIT Margin rose 5006.0% year-over-year to 52.36% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 62.1% (up 2014.0% YoY) and the FY2025 annual result came in at 62.1%, up 2014.0% from the prior year.
- EBIT Margin fell to 52.36% in Q4 2025, from 34.56% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 37.19% in Q4 2021 to a low of 225.16% in Q1 2021.
- A 5-year average of 92.27% and a median of 86.07% in 2022 frame the typical range for EBIT Margin.
- The widest YoY moves for EBIT Margin: up 15261 bps in 2022, down 13805 bps in 2022.
- Tracing KPTI's EBIT Margin over 5 years: stood at 37.19% in 2021, then plunged by 371 bps to 100.86% in 2022, then decreased by 11 bps to 112.03% in 2023, then rose by 9 bps to 102.42% in 2024, then surged by 49 bps to 52.36% in 2025.
- The last three EBIT Margin figures came in at 52.36% (Q4 2025), 34.56% (Q3 2025), and 64.3% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 17.93% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -0.36% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.75% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -35.57% |
| 10 | Karyopharm Therapeutics | 53.25 Mn | 53.25 Mn | 32.35 Mn | -67.38% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -67.38% |
| Dec 31, 2025 | -52.36% |
| Sep 30, 2025 | -34.56% |
| Jun 30, 2025 | -64.30% |
| Mar 31, 2025 | -110.80% |
| Dec 31, 2024 | -102.42% |
| Sep 30, 2024 | -67.77% |
| Jun 30, 2024 | -65.72% |
| Mar 31, 2024 | -101.91% |
| Dec 31, 2023 | -112.03% |
| Sep 30, 2023 | -86.81% |
| Jun 30, 2023 | -78.70% |
| Mar 31, 2023 | -79.85% |
| Dec 31, 2022 | -100.86% |
| Sep 30, 2022 | -85.32% |
| Jun 30, 2022 | -108.14% |
| Mar 31, 2022 | -72.55% |
| Dec 31, 2021 | 37.19% |
| Sep 30, 2021 | -116.25% |
| Jun 30, 2021 | -217.02% |